A New Roadmap for Precision in Histone Deacetylase Research
A new publication in ACS Pharmacology & Translational Science provides a critical resource for pharmacologists by recommending specific, validated tool compounds for targeting distinct isoforms and classes of histone deacetylase (HDAC) enzymes. This guide addresses a key challenge in drug discovery and pharmacodynamics research: the lack of selective inhibitors to accurately probe the biological functions of individual HDACs. The recommendations are designed to improve the reliability of preclinical studies investigating enzyme inhibition, signal transduction pathways, and the therapeutic potential of epigenetic modulators in areas like cancer therapeutics and neuropharmacology.
Study Significance: For researchers in pharmacology and drug development, this work directly impacts the design of robust, reproducible experiments by clarifying which small-molecule drugs offer true isoform specificity. This precision reduces off-target effects in mechanistic studies, accelerating the identification of viable drug candidates with optimized receptor binding and efficacy profiles. It represents a strategic step toward more reliable pharmacogenomics and personalized medicine approaches targeting epigenetic pathways.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
